Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2015-A01976-43 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the PREDOMOS study is to evaluate the impact of establishing a Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance (PS-DR) on the improvement of quality of life of elderly patients, isolated or at risk of isolation, treated for locally advanced or metastatic cancer.
In France, social isolation and prevalence of cancer increases with the population ageing: it is estimated that in 2050, 1 of 2 cancers will be diagnosed in patients over than 75 years old. Meanwhile, the share of isolated elderly increased from 16 to 24% between 2010 and 2013. It is shown that socially precarious elderly have an increased risk of dying from cancer.
Among the areas of Comprehensive Geriatric Assessment (CGA), social assessment is crucial. It can be assessed by a self-administered 8 items questionnaire, derived from MOS-SS (Medical Outcomes Study Social Support Survey) and validated in the elderly supported for cancer: m-MOS-SS (modified Medical Outcomes Study Social Support).
Once spotted, social isolation can be averted by appropriate measures, provided the intervention of a multidisciplinary team. In this area, the techniques of automation and remote assistance might have an interest. They already demonstrated their impact on falls prevention, addiction, feelings of social isolation and quality of life. However, little is known about the impact of social isolation in elderly patients supported for cancer.
The objective of the PREDOMOS study is to evaluate the impact of establishing a Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance (PS-DR) on the improvement of quality of life of elderly patients, isolated or at risk of isolation, treated for locally advanced or metastatic cancer.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Interventional arm PS-DR | Experimental | The interventional arm (PS-DR) will include the implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance (in connection with a call center 24h/24). |
|
| Reference Arm | No Intervention | In the reference arm, patients will have a conventional oncological care, social support measures will be left to the discretion of the clinician and the paramedical team. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance | Other | Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance |
| Measure | Description | Time Frame |
|---|---|---|
| Measure of the quality of life by EORTC-QLQc30 scale 3 months after treatment start | The "global health" score will constitute the main judgment criteria | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Time to failure of first line of treatment | Time between inclusion and treatment failure, whatever the cause | From date of inclusion until treatment failure, up to 6 months |
| First line of treatment toxicity at the end |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Aurélie DAUMAS, Dr | Contact | 04 91 38 87 19 | +33 | aurelie.daumas@ap-hm.fr |
| Anne-Laure COUDERC | Contact | 04 91 34 45 30 | anne-laure.couderc@ap-hm.fr |
| Name | Affiliation | Role |
|---|---|---|
| Jean-Olivier ARNAUD | Assistance Publique HĂ´pitaux de Marseille | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assistance Publique HĂ´pitaux de Marseille | Recruiting | Marseille | 13005 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30646923 | Derived | Couderc AL, Nouguerede E, Baumstarck K, Loubiere S, Le Caer H, Guillem O, Rousseau F, Greillier L, Norguet-Monnereau E, Cecile M, Boulahssass R, Le Caer F, Tournier S, Butaud C, Guillet P, Nahon S, Kirscher S, Diaz N, Morando C, Villani P, Auquier P, Daumas A. PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trial. Trials. 2019 Jan 15;20(1):54. doi: 10.1186/s13063-018-3127-0. | |
| 28403911 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Measured by Toxicity scale NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events, version 4.0).
| 12 months |
| Assessment of the number of chemotherapies received by patient compared to the number of prescribed chemotherapies | Treatment compliance | 12 months |
| Assessment of the patient dependency level determined by evaluating the Daily living activities (ADL) with the Katz scale | 3 months and 6 months |
| Assessment of the patient dependency level determined by evaluating the- instrumental activities across Lawton scale | 3 months and 6 months |
| Nutritional assessment at 3 months and 6 months | Body mass index (BMI) is the ratio of weight to height in cm squared. | 3 months and 6 months |
| Functional assessment at 3 months and 6 months | The unipodal station is to stand on one foot without aid. A unipodal station less than 5 seconds indicating a high risk of falls (46). | 3 months and 6 months |
| Overall Survival defined as the time between chemotherapy start and death | will be assessed at 6 months and 1 year | up to 12 months |
| Progression free Survival defined as the time between treatment start and the date of first documented progression or death, whatever the cause. | Time to progression is the time elapsed between the date of treatment start and the occurrence of progression or relapse if a response was observed (response or stabilization). A patient who has not progressed or who did not die at the limit of 1 year will have its censored survival time when tumor enough last evaluation conducted by the deadline of 1 year . The progress will then be defined according to the criteria RECIST1.1 . In case of death , it will be identified if it is related to tumor progression , toxicity or complication of treatment or another cause (non-specific death). | up to 12 months |
| Social isolation | Social isolation will be measured by the m -MOS questionnaire. A result < 80% is recognized as the consensus inferior value below which patients are socially isolated position | 12 months |
| Measure of the "global health score" to assess the quality of life at first line of treatment | 3 months and 6 months |
| Derived |
| Cretel-Durand E, Nouguerede E, Le Caer H, Rousseau F, Retornaz F, Guillem O, Couderc AL, Greillier L, Norguet E, Cecile M, Boulahssass R, Le Caer F, Tournier S, Butaud C, Guillet P, Nahon S, Poudens L, Kirscher S, Loubiere S, Diaz N, Dhorne J, Auquier P, Baumstarck K. PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: study protocol for a randomized controlled trial. Trials. 2017 Apr 12;18(1):174. doi: 10.1186/s13063-017-1894-7. |
| ID | Term |
|---|---|
| D009362 | Neoplasm Metastasis |
| ID | Term |
|---|---|
| D009385 | Neoplastic Processes |
| D009369 | Neoplasms |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided